NCT07718581 HMPL-A830 Solid tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07718581 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07718581 is a hot trial to watch
Solid tumor is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07718581 is notable because it evaluates HMPL-A830 in a Phase 1/2 design sponsored by HUTCHMED (China) Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07718581 |
| Official title | HMPL-A830 in Solid Tumors |
| Phase / status | Phase 1/2 / Not yet recruiting |
| Intervention | HMPL-A830 |
| Sponsor | HUTCHMED (China) Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | DLTs |
| Endpoint time frame | Approximately 12 months |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This is a first-in-human (FIH), multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors*, who are refractory or progressed on/after available standard treatment. The study will be conducted in 2 parts: Dose Escalation (Part A, Phase I), approximately 57 participants will be enrolled. Dose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.
Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- DLTs (Approximately 12 months) — Number of Participants With of DLTs
- Overview of Treatment-emergent Adverse Events (TEAEs) (Approximately 12 months) — The number of participants with Adverse Events and Treatment-Related Adverse Events as Assessed by CTCAE v6.0
- Objective Response Rate (ORR) (Approximately 24 months) — Assessed by investigators according to RECIST 1.1
- Recommended doses for phase II or III studies (RP2D or RP3D) (Approximately 12 months) — The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: HMPL-A830 is indexed as Antibody drug conjugate (ADC), with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status Phase 1/2.
Company & Deal Intelligence MCP profile: HUTCHMED (China) Ltd. is resolved to a normalized organization record in Hong Kong SAR, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07718581 provides a focused lens on Solid tumor development. Its value will be determined by whether HMPL-A830 can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
